Abstract:Abstract Genomic instability is the hallmark of various cancers with the increasing accumulation of DNA damage. The application of radiotherapy and chemotherapy in cancer treatment is typically based on this property of cancers. However, the adverse effects including normal tissues injury are also accompanied by the radiotherapy and chemotherapy. Targeted cancer therapy has the potential to suppress cancer cells’ DNA damage response through tailoring therapy to cancer patients lacking specific DNA damage response functions. Obviously, understanding the broader role of DNA damage repair in cancers has became a basic and attractive strategy for targeted cancer therapy, in particular, raising novel hypothesis or theory in this field on the basis of previous scientists’ findings would be important for future promising druggable emerging targets. In this review, we first illustrate the timeline steps for the understanding the roles of DNA damage repair in the promotion of cancer and cancer therapy developed, then we summarize the mechanisms regarding DNA damage repair associated with targeted cancer therapy, highlighting the specific proteins behind targeting DNA damage repair that initiate functioning abnormally duo to extrinsic harm by environmental DNA damage factors, also, the DNA damage baseline drift leads to the harmful intrinsic targeted cancer therapy. In addition, clinical therapeutic drugs for DNA damage and repair including therapeutic effects, as well as the strategy and scheme of relative clinical trials were intensive discussed. Based on this background, we suggest two hypotheses, namely “environmental gear selection” to describe DNA damage repair pathway evolution, and “DNA damage baseline drift”, which may play a magnified role in mediating repair during cancer treatment. This two new hypothesis would shed new light on targeted cancer therapy, provide a much better or more comprehensive holistic view and also promote the development of new research direction and new overcoming strategies for patients.

DNA Repair Inhibition: a Selective Tumour Targeting Strategy.

Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance.

Targeting the DNA Repair Pathway for Breast Cancer Therapy: Beyond the Molecular Subtypes.

DNA Damage and Its Role in Cancer Therapeutics

DNA Repair Pathways in Cancer Therapy and Resistance.

Targeting DNA damage response pathways in cancer

Recent Advances in Cancer Therapy Targeting Proteins Involved in DNA Double-Strand Break Repair

Dual Targeting of DNA Damage Response Proteins Implicated in Cancer Radioresistance

DNA Repair and Resistance to Topoisomerase I Inhibitors: Mechanisms, Biomarkers and Therapeutic Targets

Perspectives on the Combination of Radiotherapy and Targeted Therapy with DNA Repair Inhibitors in the Treatment of Pancreatic Cancer.

Targeting DNA Repair Pathways: Mechanisms and Potential Applications in Cancer Therapy

Emerging Cancer Therapeutic Opportunities Target DNA-repair Systems

Targeting DNA Double-Strand Break (DSB) Repair to Counteract Tumor Radio-resistance

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy

DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications

Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer Therapy

Targeted Inhibition of DNA-PKcs, ATM, ATR, PARP, and Rad51 Modulate Response to X Rays and Protons

Enhancing the Anti-Tumor Response by Combining DNA Damage Repair Inhibitors in the Treatment of Solid Tumors

Exploiting DNA repair pathways for tumor sensitization, mitigation of resistance, and normal tissue protection in radiotherapy

Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal Cancer